Company Presentation

1

Disclaimer

This presentation has been produced by Medios AG (the „Company“) and is strictly

confidential. The distribution of this presentation in certain jurisdictions is restricted by law

and persons into whose possession this presentation comes should inform themselves

about, and observe, any such restrictions. This presentation is furnished to you solely for

your information and may not be copied, distributed or otherwise made available, in

whole or in part, to any other person.

The facts and information contained herein are as up to date as is reasonably possible and

are subject to revision in the future. None of the Company or its directors, officers,

employees or advisors nor any other person makes any representation or warranty, express

or implied as to, and no reliance should be placed on, the accuracy or completeness of the

information contained in this presentation. None of the Company or any of its directors,

officers, employees and advisors nor any other person shall have any liability whatsoever for

any loss howsoever arising, directly or indirectly, from any use of this presentation. The same

applies to information contained in other material made available at the presentation. While

all reasonable care has been taken to ensure the facts stated herein are accurate and that

the opinions contained herein are fair and reasonable, this presentation is selective in nature

and is intended to provide an introduction to, and overview of, the business of the Company.

Where any information and statistics are quoted from any external source, such information

or statistics should not be interpreted as having been adopted or endorsed by the Company

as being accurate.

This presentation contains certain forward-looking statements relating to the business,

financial performance and results of the Company and /or the industry in which the

Company operates. Forward-looking statements concern future circumstances and results

and other statements that are not historical facts, sometimes identified by the words

»believes«, »expects«, »predicts«, »intends«, »projects«, »plans«, »estimates«, »aims«,

»foresees«, »anticipates«, »targets« and similar expressions in English or equivalent

expressions in German.

The forward-looking statements, including but not limited to assumptions, opinions and

views of the Company or information from third party sources, contained in this presentation

are based on current plans, estimates, assumptions and projections and involve uncertainties

and risks. Various factors could cause actual future results, performance or events to differ

materially from those described in these statements. The Company does not guarantee that

the assumptions underlying such forward-looking statements are free from errors nor does it

accept any responsibility for the future accuracy of the opinions expressed in this

presentation or the actual occurrence of the forecasted developments. No obligation is

assumed to update any forward-looking statements.

This presentation does not constitute or form a part of, and should not be construed as,

an offer or invitation to subscribe for, or purchase, any securities and neither this

presentation nor anything contained herein shall form the basis of, or be relied on in

connection with, any offer or commitment whatsoever.

In particular, this presentation does not constitute an offer of securities for sale or a

solicitation of an offer to purchase securities in the United States. The shares in the

Company may not be offered or sold in the United States or to or for the account or

benefit of „U.S. persons“ (as such term is defined in Regulation S under the U.S. Securities

Act of 1933, as amended (the „Securities Act“)) absent registration or an exemption from

registration under the Securities Act. The shares in the Company have not been and will

not be registered under the Securities Act.

This presentation speaks as of May 2019. Neither the delivery of this presentation nor

any further discussions of the Company with any of the recipients shall, under any

circumstances, create any implication that there has been no change in the affairs of

the Company since such date.

Medios AG 05/2019

2

Manfred SchneiderChief Executive Officer

Matthias GärtnerChief Financial Officer

Mi-Young Miehler Chief Operating Officer

Christoph PrußeitChief Innovation Officer

Pharmacist

More than 20 years of pharmacy markets experience

IT-Specialist

More than 20 years offinancial marketsexperience

Business Economist

Business developmentspecialist

Pharmacist

Expert in the area of pharmaceuticals production and safety

Medios AG 05/2019

3

Management team

Group€m

327.8

12%

Supply

Manufacturing

• Strongly positioned in patient-specific medication

• 90,000 individualised preparations in 2019

• Highly focused onSpecialty Pharma drugs

• 1,000 products available

Medios at a glance Medios AG 05/2019

4

PHARMACEUTICAL SUPPLY PATIENT-SPECIFIC MANUFACTURING

Specialist for the provision of Specialty Pharma drugs to patients and GMP-certified provider of patient-specific therapies.

Specialty Pharma: Individualised Medicine, treatment of chronic and/or rare diseases, mostly time and cost intensive

BUSINESS SEGMENTS

2018 revenue split 2018 revenue split

DRUG SAFETY

• Innovative measurement-, validation- and certification method

Group€m

327.8

88%

Supply

Manufacturing

Opdivo ®(manufacturedproduct,*1

no set purchaseprice)

• Skin cancer

• Lung cancer

• Renal cell carcinoma

• Treatment: 6-12 months

• Up to EUR 160,000 per patient/year

Humira ®

• i.a.rheumatism

• Treatment:approx. 12weeks

• Up to EUR 42,000 perpatient/year

Harvoni ®

• Hepatitis C • Treatment:8-24 weeks

• Up to EUR 100,000 per therapy

Replagal ®

• MorbusFabry

• Treatment:6-54 months

• Approx. EUR300,000 per patient/year

Cancer diseases

• Breast cancer• Prostate

cancer• Leukaemia,

etc.

1,600,000

Others

Infectious diseases

Autoimmune diseases

200,000

300,000

1,500,000

Medios has the broadest Specialty Pharma product portfolio to address EUR 12.5bn market opportunity in Germany

Medios AG 05/2019

5

INDICATION CATEGORY

MEDIOS PRODUCT EXAMPLES

* incl. estimated numbers of cases per year in Germany (sources: DAlzG, bms-virologie.de, RKI, PZ, dgn.org, DGRh, Der Nervenarzt, krebsinformationsdienst.de, morbus-crohn-aktuell.de, fachinfo.de, hivandmore.de, shire.de) *1Patient-specific preparation required

Product from segment ‘Patient-specific Manufacturing’; Product from segment ‘Pharmaceutical Supply’

INDICATION

# OF PATIENTS P.A.

IN GERMANY*

PRODUCT DISEASE THERAPY (EXEMPLARY) COSTS

• Multiple Sclerosis

• MorbusCrohn

• Rheumatism

• Hepatitis C• HIV

• Alzheimer• ALS• Morbus Fabry

450,00088,400

1,000,0008,0002,000

44,6

45,8

47,848,2

49,1

2013 2014 2015 2016 2017

Pharmacies turnover in Germany (in EUR bn)

100

123

149158

192

100 106 111 108 111

2013 2014 2015 2016 2017

Revenue Specialty Pharma Drugs* vs. Revenue other RX-Drugs (in %)

Specialty Pharma Drugs

RX-Drugs

* Sources: Arzneiverordnungsreport 2018, ABDA Zahlen, Daten, Fakten 2018; *1Patient-specific preparation required

REVENUE OF PHARMACIES IN GERMANY 2017

Dynamic market development in Germany

1/3Manufactured products*1

Market environment

2/3Finished medicinal products

Total revenue

EUR 49.1bn +1.9% yoy

EUR 39.4bn -1.0% yoy

Rx drugsrevenue

EUR 12.5bn forecast: 10% yoy

Specialty pharmadrugs revenue*

thereof

thereof

Medios AG 05/2019

6

Strong underlying drivers for future market growth

DEVELOPMENT OF NEW ACTIVE PHARMACEUTICAL INGREDIENTS PATIENT-SPECIFIC MEDICINE DEMOGRAPHIC CHANGE

New therapies mainly focused on rare,

chronic or genetic diseases

Diagnostics and therapies are increasingly individualised

– impact of gene based medical knowledge

Considerable increase in chronic diseases due to an ageing population

Expected market growth of Specialty Pharma in Europe by 2020: ~ 10% p.a.*

Medios AG 05/2019

7

*Source: IMS Health, forecast for growth 2015 – 2020 for Spain, Italy, France, UK and Germany

Market environment

Medios is a highly specialised partner for Specialty Pharma Drugs across Germany

Medios AG 05/2019

8

OnkologyAutoimmune

Infectious DiseasesOther

INDICATION SPECIFIC PARTNERS

More than 180 specialised partners nationwide (as of May 2019)

Coverage of the entire Specialty Pharma market:

various indications

BENEFITS FOR PARTNERS

Attractive purchasing and payment conditions

Optimised purchasing management:planning and bundling of our partners needs

Ensuring delivery capability

Market positioning

STRONG PARTNER NETWORK ACROSS GERMANY

Pharmaceutical Supply: ‘Classic’ trading structure of full-range wholesale

Medios AG 05/2019

9

Standard condition agreements on the entire range of products of the respective manufacturer – approx. 100,000 products

Pharmaceutical Company 1 Pharmaceutical Company 2 Pharmaceutical Company 3

Market positioning

Medios AG 05/2019

10

Individual conditions agreement at individual product level max. 1,000 specialty pharma drugs

Pharmaceutical Company 1 Pharmaceutical Company 2 Pharmaceutical Company 3

Pharmaceutical Supply: Medios’ innovative trading structureMarket positioning

19.500

1,000

Full Range Wholesaler

Medios

11

100,000

1,000

20

1

EUR 39.4 bn

EUR 12.5 bn

All Highlyspecialised Pharmacies

Fullassortment

of Drugs

Specialty Pharma Drugs

Regionalwarehouses

Centralwarehouse

Rx-Drugs Specialty Pharma Drugs

MARKET POTENTIALDISTRIBUTIONSYSTEMPRODUCT RANGEPHARMACIES

IN GERMANY

Medios AG 05/2019

~5% 1% 5%

31.8%

Pharmaceutical Supply: Medios is highly focused and highly efficient

Market positioning

DOCTOR

• Order received at the pharmacy

PHARMACY

• Validation of the prescription

• Order placed at Medios

• Additional confirmation of the prescription

• Manufacture of the medical preparation in accordance with GMP

PHARMACY

• Fast delivery to the doctor –invoice to the insurer

DOCTOR

• Timely administration of the prescription

Patient-specific Manufacturing: Medios is the only player at scale covering a broad range of indications

Medios AG 05/2019

12

• Nationwide supply with individualised application ready infusions for various indication areas (e.g. oncology, neurology, gastroenterology)

• Production complies with highest quality standard GMP

• More than 60,000 preparations in 2018

• Approx. 90,000 preparations in 2019 (+50% yoy)

• 10 workstations at two production sites in Berlin

• Cost & process synergies with segment ‘Pharmaceutical Supply’

Patient-specific medication process in Germany Strongly positioned in patient-specific medication

Market positioning

• Full-line wholesalers (approx. 100,000 products)• Primarily a logistics partner not a consulting partner• Mandatory legal inventory range

of 14 days• Intransparent discount structures

• Mainly regional focus• Primarily manufacturers,

not consulting partners• Limited range

• Limited range• Focus on niche segments and special processes

• Limited capacity• No GMP certification

• Less cost effective manufacturing

Medios is strongly positioned in the competitive environment Medios AG 05/2019

13

more than 200 pharmacies

with clean room laboratory

Diagram is an example / Source: ABDA; * Pharmacies with approved clean room laboratory

Market positioning

35%63%

82% 76%65%

37%

18%24%

2.8

5.8

8.0

11.0

14.5-15.5

Proven financial track record with strong profitable growth Medios AG 05/2019

14

Revenue in EUR m

Adj. EBT in EUR m

*2015 and 2016 pro-forma; *1CAGR = Compound Annual Growth Rate; *2Adjusted for extraordinary expenses e.g. stock options

Pharmaceutical Supply

Patient–specific Manufacturing

2015* 2016*

Key Financials

2017*² 2018*² 2019E*²

62%75%

83%88%

38%25%

17%

12%

90160

254

328430-440

Pharmaceutical Supply

Patient–specific Manufacturing

Adj. EBT Margin 3.1% 3.6% 3.2% 3.4% 3.3-3.6%

Medios Group IFRS

AnalyticsMedios Group

Medios AG 05/2019

15

• Currently more than 180 pharmacies covered

• Cover 300pharmacies mid-term

• Cover 1,000pharmacies long-term

Grow customer base and partner

network

E-COMMERCE• Roll-out Specialty

Pharma tradingplatform for all market players

EFFICIENCY• Roll-out

individualisedsoftware solutionsfor increasedefficiency andmarginoptimization

MARKETINTELLIGENCE• Roll-out

innovative datacluster model

Benefit from digitalisation

• Introduce and roll-out innovative NIR spectroscopy analytics service

• Set up third business segment “Analytics”

Expand into Analytics

Extend product range and

expandto further

indication areas

We have an organic growth strategy in place to be the leading provider of Specialty Pharma solutions in Germany

Growth strategy

• Currently more than 400 specialty pharma drugs offered

• Extendoffering to 1,000 specialty pharma drugs

Patient-specific Manufacturing

• Increase in margins due to significant economies of scale

Utilise existing capacities

Expand existing production capacities

• Currently90,000individualised therapies

• Possibility to expandcapacity to up to 200,000 individualised therapies

NUMBER OF PATIENT-SPECIFIC PREPARATIONS

Increase in margins due to significant economies of scale

40.000 60.000 90.000 100.000

200,000

*CAGR – Compound Annual Growth Rate

2017 2019 2020 Max. potential at existing sites2018

Patient-specific Manufacturing: Utilise existing and expand capacities; Scalability of production capacity at existing sites (10 workstations)

Medios AG 05/2019

16

Growth strategy

EXTRACTION OF SAMPLE ANALYSIS CERTIFICATION PROCESS

• Rubber seal of vial is perforated

• Drug no longer sterile and therefore useless

• Hours to days until result

• Incoming drug in quarantine

• No batch release untilsucessful test result available

• Release and certification of incoming drug material or rejection

• Complete disposal of test sample

17

Drug Safety: Traditional drug testing Medios AG 05/2019

Research & development

MEASUREMENT DATABASE CERTIFICATE

• Measurement by non-destructive method

• Analytical results available within less than 3 minutes

• Alignment with Mediosindividual Database

• Increase in validity basedon continuously growingdatabase (intelligent cloudsystem)

• Medios allowed to issue certificates for third parties as proof of authenticity

18

Drug Safety: Innovative NIR* Spectroscopy Medios AG 05/2019

* Near-infrared

Research & development

Example: Velcade®, 15 batches, 5 samples each. Reference rangeAnalysed productWithin the range, reduced quality (degredation)

19

Falsified products

Drug Safety: The Medios Approach (patent pending)Research & development

Key investment highlights Medios AG 05/2019

20

1 Highly attractive and strongly growing Specialty Pharma market driven by structural tailwinds

MARKET

2 Uniquely positioned as first mover with clearly defined competitive advantages within the field of individualised medicine

POSITIONING

3 Strong, synergistic business model with clear value-add for stakeholdersBUSINESS MODEL

4 Proven financial track record with continuous, profitable asset-light growthFINANCIALS

5 Highly experienced founder-led management team with clear strategy for profitable growth

STRATEGY

21

Medios AG 05/2019